including 4,900 in France.
98% of Servier brand-name medicines
active ingredients are synthesized in France.
in which the Group’s medicines are distributed
4 R&D therapeutic areas
oncology, cardiometabolism, neurosciences and immuno-inflammation
in clinical development, including 26 new molecular entities (May 2021).
A strong international presence
96% of Group revenue (from brand-name medicines) generated outside France.
16 chemical and pharmaceutical production sites
15 International Centers for Therapeutic Research
and 5 R&D centers (2 in France, 1 in Denmark, 1 in Hungary and 1 in the US).
€4.7 billion euros in revenue
comprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines.
23% of revenue from brand-name medicines invested in R&D
31st largest pharmaceutical Group worldwide
and 2nd largest pharmaceutical Group in France.
A leader position in cardiology in France
6th leading pharmaceutical Group worldwide.
Participation reached 36% of the trade balance surplus in France
in pharmaceuticals and fine chemicals (brand-name medicines), amounting to €1.6 billion.